Oncocidia Ltd.

Oncocidia Ltd.

Pharmaceutical Manufacturing

Amersham, Buckinghamshire 116 followers

A novel radiopharmaceutical anti-cancer agent

About us

The Company is developing a targeted radiopharmaceutical cancer treatment called Oncocidia. The treatment is based on a novel small-molecule compound 131I-Hyp (hypericin labelled with Iodine-131), which targets and destroys partially necrosed tumors. Oncocidia is indication agnostic and can be applied to a wide range of solid tumors. It is particularly suited to use as an adjuvant to existing treatments where necrosis is created. Extensive programs of in vitro and in vivo pre-clinical research have been undertaken and published, and a clinical standard formulation of the compound has been developed. A Phase I clinical trial is in planning, for launch in early 2020. Market authorization for selected indications is targeted for 2024.

Industry
Pharmaceutical Manufacturing
Company size
2-10 employees
Headquarters
Amersham, Buckinghamshire
Type
Privately Held
Founded
2016
Specialties
Oncology and Radiotherapeutics

Locations

  • Primary

    Anglo House, Bell Lane

    Amersham, Buckinghamshire HP6 6FA, GB

    Get directions

Similar pages

Browse jobs